TABLE 5.

HSV Keratitis Incidence

Location	Incidence^a	Rationale	Author(s)	Population^b	Incidence in Population (per year)
France	25.8	Combined incidence of epithelial and stromal keratitis (high probability)	Labetoulle et al³⁷	65,102,719	16,797
USA	18.2	Combined incidence of epithelial and stromal keratitis	Liesegang et al⁴⁵	313,232,044	57,008
Developed nations	23.3	List of nations included: Norway, Australia, New Zealand, USA, Ireland, Liechtenstein, Netherlands, Canada, Sweden, Germany, Japan, South Korea,^c Switzerland, France, Israel, Finland, Iceland, Belgium, Denmark, Spain, Hong Kong, Greece, Italy, Luxembourg, Austria, UK, Singapore, Czech Republic, Slovenia, Andorra, Slovakia, U.A.E., Malta, Estonia, Cyprus, Hungary, Brunei, Qatar, Bahrain, Portugal, Poland, Barbados Incidence from U.S. extrapolated to Canada Incidence from France extrapolated to remaining developed nations	(extrapolated data)	1,036,895,491	241,597
Developing nations	Unknown	All nations not included in list of developed nations Incidence from developed nations extrapolated to developing nations as a minimum estimate^d	(extrapolated data)	5,891,302,762	1 to 1.5 million

Developed nations were categorized as having “very high human development” by the United Nations Development Program. There is as such no agreed upon definition for developed versus developing nations.

Incidence values are given per 100,000 person-years.

Populations based on estimates from the U.S. Bureau of the Census and the Central Intelligence Agency World Factbook, updated 2011.

South Korea is officially the Republic of Korea.

Incidence rates were extrapolated from the French and U.S. studies to the population of the developing world. If our assumption is correct that the rates of HSV keratitis incidence are at least as high in the developing world as they are in the developed world, then this may provide us with a minimum estimate. Adding the estimates for developed and developing nations provides a combined annual global incidence of roughly 1.5 million.